With a highly concentrated population, a single-payer system, and vast hospital capacity (90,000 beds in Seoul vs. 4,000 in Boston), South Korea offers a significant advantage for clinical development. This infrastructure allows trials to be completed 40% faster and at 40% lower cost compared to the US.

A key solution to clinical trial delays is for elite NCI-designated cancer centers to accept each other's IRB approvals. If a protocol is approved by MD Anderson, for example, Fred Hutch should honor it without a redundant review. This would eliminate months from the study startup phase.

The US regulatory regime for early clinical trials is so slow that companies are opting for more efficient systems, like Australia's local IRB-based approval. This offshoring of initial research puts the US at a global competitive disadvantage in generating crucial early data.

Long-standing bottlenecks in U.S. first-in-human trials are finally being addressed due to intense competitive pressure from China. This has created a rare sense of urgency among U.S. policymakers, the FDA, and academic centers, forcing them to modernize processes that have been slow for years.

For a smaller company, conducting a clinical trial within one country like the UK is highly efficient. It streamlines regulation under one agency (the MHRA), reduces costs, and allows for rapid patient enrollment by leveraging a tight-knit national network of clinical specialists.

The FDA's "Operation Trial Blazer" reforms will cut US trial launch times in half, to 15 months, but this is still seven months slower than China. The US approach focuses on making sequential processes more efficient, whereas China's model runs regulatory, ethics, and preclinical work in parallel—a higher-risk but faster strategy.

A key operational hurdle for European clinical trials is the absence of a mandatory response timeline for regulators. Unlike the US FDA, which must respond to trial applications within 30 days, European regulators have no fixed "shot clock," creating uncertainty and delays that deter trial sponsors.

While the US views China's efficiency in first-in-human (FIH) trials as a geopolitical threat, the real issue is a slow, bureaucratic status quo. China's progress is a catalyst forcing global regulators to prioritize patient access and streamline development, shifting the focus from national competition to systemic innovation.

Unlike the U.S. system, which often requires separate ethics reviews for each trial location, China has adopted a "parallel ethics" model. If one site's ethics committee approves a trial, that approval extends to all other participating sites, drastically reducing administrative delays.